upper end guid less like
confid sustain growth double-digit
earn remain high libr mitraclip remain
key catalyst next six month along balanc
sheet deploy remain sourc upsid vs model
abbott line expect abbott deliv organ growth
line mse deliv momentum stabil preview see
expect libr approv opioid liabil weigh share
perform quarter drive modest out-performance
result see propos opioid settlement nutrit deceler bp
comp adjust due china pediatr weak diagnost acceler
bp delay ngo contract bp total
abbott growth headwind quarter mdx/aler epd deceler
pt expect cardio/neuromod stabl rm acceler pt
neuromod deceler pt market condit remain challeng
discuss ep vs mse impact fx
headwind expect discuss key driver growth mitraclip
libr
outlook manag guid organ growth impli
midpoint rang upper half rang
less like may explain pediatr nutrit challeng lack
resolut ngo contract dx lesser extent lack neuromod
recoveri outsid dynam see materi chang
underli busi traction comfort
organ growth line guidanc impli bp momentum
deceler see pocket upsid driven resolut ngo
contract dx could benefit libr
epd collect repres bp upsid vs
estim ep comfort low end
rang updat fx bp headwind increment
organ double-digit earn like ceo mile white
commentari suggest organ growth seen prior eight quarter
sustain underli trend busi remain larg
stabl remain comfort organ growth
organ growth nutrit bp deceler
high end end market growth assum growth dx
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
bp deceler alin roll-out build note high-
momentum model growth epd line trend
model growth cardio/neuromod repres
momentum stabil heart failur slow high singl digit
heartmat impact channel season neuromod growth return
low singl digit easier comp
key growth driver model y/i diabet growth impli
point deceler growth may prove conserv continu
reflect impact libr driven inflect assum bgm
pressur remain high teen structur heart improv
high teen driven mitraclip/portico estim could prove
conserv pend time mitraclip ncd lesser extent
portico launch
ep comfort y/i growth line
driven bp margin expans account fx
headwind bp sale earn
robert ford took promin posit earn call
continu expect mile white transit announc
mitraclip libr drive bp growth
contribut remain similar
libr libr sale approach beat mse
patient ad quarter libr remain focu
manag reiter confid icgm approv conced
process taken longer expect expect approv
approv possibl model ww libr
sale base mid-teen q/q growth us high singl digit q/q
growth ex us driver growth includ pharmaci coverag
stand ii new manufactur prior capac
allow abbott push aggress channel dtc
ex us expans libr driven inflect remain exclud
estim note increment sale bp
mitraclip us mitraclip deliv y/i growth acceler
pt pt acceler ex us mitraclip saw sequenti
improv cc growth mitra-fr anniversari
expect increment step estim
us growth includ ncd driven acceler expect ncd
may/jun late possibl note increment
improv us sale increment bp abbott growth
premium top bottom line grower compon upgrad
overweight come continu includ peer lead organ
growth continu margin expans peer net leverag creat
option expect elev theme remain
evid abbott deliv prior quarter
outlook sustain intermedi term bp margin
expans low doubl digit low teen ep growth look sustain
least next year top quartil among tradit larg cap peer
abbott announc new repurchas agreement dont expect activ
repurchas larg said leverag drop
would like see growth-ori tuck-in spur growth pt
base ep ep premium large-cap
peer group line high-growth large-cap devic peer
price target base multipl
base case ep line high growth larg cap peer
see multipl reflect abbott
better peer top bottom line growth
bull case ep
bull case ep
new product launch libr confirm mitraclip tam expans
inflect quicker expect upsid synergi robust em end
market provid tailwind nutrit stage strong recoveri larg share
gain china abbott abl deliv revenu cost
synergi st jude aler result increment margin expans
base ep
base ep
nutrit recov china imf headwind fade aler stabil gradual
return market growth new product libr confirm mri
launch mitraclip inflect sustain organ growth profil
medium term management execut deal synergi margin grow
per year support ep base case valuat use price-to-earnings valuat
larg cap peer believ justifi given better top
bottom line growth line high growth peer
bear ep
bear ep
libr fail gain traction us confirm mitraclip adopt slower
expect neuromodul grow slow singl digit nutrit end
market take longer recov aler revenu continu declin aler
st jude synergi target prove overli optimist abbott invest grow
revenu offset margin improv em slowdown persist
abbott organ growth sustain
driven broad busi momentum
key product growth libr mitraclip
abbott high exposur emerg
market consumer-direct busi
drive potenti sustain double-
digit earn growth also subject
compani em currenc exposur
highest among devic coverag
leverag opportun visibl across
nutrit diagnost epd peer
margin demonstr potenti
evid execut st jude aler
synergi target demonstr
improv aler organ growth rate
critic ep upsid maintain
organ growth acceler driven
devic product launch diabet ep
heart failur
continu oper margin expans
core abbott combin cost synergi
execut st jude aler
devic libr reimburs us
on-going libr launch
miraclip fmr approv
risk achiev price
emerg market macro slowdown fx
headwind strengthen us dollar
failur deliv synergi target and/or
growth acceler aler failur
libr mitraclip drive top-line growth
million except ep
million except ep
point
cardiovascular neuromodul
lsd msd
msd hsd
msd hsd
cardiovascular neuromodul
lsd msd
guidanc
similar
product sale
point total
cardiovascular neuromodul
cardiovascular neuromodul total
defer incom tax prepaid receiv
defer incom tax
s/t debt current portion lt debt
liabil deferr
common share net treasuri stock
accum comp incom
point total
